Acrux Limited (ASX:ACRO)

Australia · Delayed Price · Currency is AUD · Option

0.0010

0.00 (0.00%)

At close: May 28, 2026

-50.00% (1Y)

Market Cap	5.73M -68.7%
Revenue (ttm)	1.19M -76.6%
Net Income	-5.95M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	2.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,543,510
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0010 - 0.0020
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 25, 2025

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazo... [Read more]

Industry Pharmaceutical Preparations

Founded 1998

Employees 43

Stock Exchange Australian Securities Exchange

Ticker Symbol ACRO

Full Company Profile